AMAdekunle Muiz Mofolorunso

Adekunle Muiz Mofolorunso

*This is an algorithmically generated author record based on publicly available information.

Adekunle Muiz Mofolorunso has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gut Microbiota Modulation in Parkinson’s Disease: Exploring Phytotherapy, Pharmacotherapy, and Precision Interventions

    by Samuel Oluwadare Olalekan, Patrick Godwin Okwute, Ifabunmi Oduyemi Osonuga, Adekunle Muiz Mofolorunso, Bukunola Oluyemisi Adegbesan, Esther Nkechi Ezima, Gideon Olamilekan Oluwatunase

    Parkinson’s disease (PD) is a progressive neurodegenerative disorder with growing evidence implicating gut microbiota dysbiosis in its pathogenesis. Recent research highlights the gut-brain axis as a crucial therapeutic target, with interventions such as phytotherapy, pharmacotherapy, and precision medicine emerging as promising approaches. Phytotherapy, including plant-derived compounds like curcumin and dioscin, has demonstrated neuroprotective effects by modulating gut microbiota, reducing neuroinflammation, and enhancing short-chain fatty acid production. Pharmacotherapy, particularly levodopa, remains the primary treatment for PD motor symptoms, but its interactions with gut microbiota can affect drug metabolism, necessitating microbiota-targeted strategies such as enzyme inhibitors and antibiotic co-administration. Precision interventions, including probiotics, prebiotics, synbiotics, dietary modifications, and fecal microbiota transplantation, aim to restore microbial balance and improve gut-brain axis function. This chapter explores the mechanisms, clinical outcomes, and limitations of these interventions, emphasizing the need for integrative and personalized therapeutic approaches. By targeting gut microbiota, these strategies hold potential for optimizing PD management, enhancing treatment efficacy, and improving patient quality of life.


  • Open Access

    The Complex Interplay: Unfolding the Mechanisms of Chronic Obstructive Pulmonary Disease

    by Patrick Godwin Okwute, Adekunle M. Mofolorunso, Gideon Olamilekan Oluwatunase, Olayinka Olawale Asafa, Samuel Olalekan, Onome Bright Ogenetega, Oyovwi Mega Obukohwo

    Chronic obstructive pulmonary disease (COPD) is a widely prevalent respiratory ailment that can be prevented. It is characterized by the chronic restriction of airflow caused by lung abnormalities resulting from exposure to toxic chemicals or particles. COPD is a respiratory disorder characterized by a gradual and incapacitating progression, impacting a significant number of individuals on a global scale. COPD is distinguished by the presence of chronic bronchitis and emphysema, resulting in considerable morbidity and mortality. The etiology of COPD is multifaceted, encompassing genetic, environmental, and physiological variables. In spite of the existence of global health objectives, the incidence and mortality rates of COPD persistently escalate, exhibiting disparities influenced by factors such as gender, geographical location, and age. The increasing prevalence of COPD, therefore, necessitates a pressing requirement for enhancing treatment approaches and patient outcomes.